Stephanie J. Phelps | Akateeminen Kirjakauppa

The Teddy Bear Book is the only reference of its kind that focuses on the unique issues that healthcare professionals face when using injectable medications in children, such as limited fluid volumes, maximum concentrations, and rates of administration.

The 12th Edition features more than 270 updated monographs (including over 40 monographs new to this edition) that cover the following areas:

Safety issues
Infusion-related cautions
Dosages and conditions requiring dosage adjustments
Contraindications and warnings
Adverse drug effects
Preparation and compatibility
Bolus, intermittent, and continuous IV administration
Monitoring
New monographs include:

Ansuvumab
Antihemophilic Factor (Recombinant) Factor VIII pegylated
Bevacizumab
Blinatumomab
Brentuximab
Brivarcetam
Calaspargase Pegol
Ceftazidime Avibactam
Ceftolozane Tazobactam
Cetirizine HCl
Crizanlizumab
Dalbavancin
Daunorubicin and Cytarabine, Liposome
Defibrotide
Dinutuximab
Dupilumab
Eculizumab
Elapegademase Lvlr
Emapalumab-lzsg
Emicizumab
Factor IX (Recombinant Albumin Fusion Protein)
Factor IX (Recombinant Fc Fusion Protein)
Factor IX (Recombinant Glycopegylated)
Factor IX (Recombinant)
Factor X concentrate (Human)
Factor XIII concentrate (Human)
Factor XIII a-subunit (Recombinant)
Ferric Carboxymaltose
Ferric Derisomaltose
Ferumoxytol
Gemtuzumab
Inotuzumab
Ipilimumab
Methoxy Polyethylene Glycol-Epoetin Beta
Nalbuphine HCl
Nivolumab
Onasemnogene Abeparvovec
Pembrolizumab
Remdesivir
Tedizolid
Tocilizumab
New features added to all monographs:

Expanded monograph layout
Pronunciations
Enhanced safety information including ASHP’s Standardize 4 Safety concentration standards, and The KIDs List
AHFS® Pharmacologic-Therapeutic Classification© specific category identification